TG Therapeutics (NASDAQ:TGTX - Get Free Report) is anticipated to release its earnings data before the market opens on Wednesday, February 26th. Analysts expect TG Therapeutics to post earnings of $0.09 per share and revenue of $100.67 million for the quarter. Parties that wish to listen to the company's conference call can do so using this link.
TG Therapeutics Stock Down 2.8 %
Shares of TG Therapeutics stock traded down $0.81 on Thursday, hitting $28.53. 1,700,339 shares of the company's stock traded hands, compared to its average volume of 2,150,958. The company has a quick ratio of 3.91, a current ratio of 4.59 and a debt-to-equity ratio of 1.27. The firm's 50-day moving average is $30.84 and its 200 day moving average is $27.97. The stock has a market cap of $4.44 billion, a P/E ratio of -285.27 and a beta of 2.26. TG Therapeutics has a 52-week low of $12.93 and a 52-week high of $36.84.
Analysts Set New Price Targets
TGTX has been the subject of several research analyst reports. The Goldman Sachs Group boosted their target price on shares of TG Therapeutics from $20.00 to $22.00 and gave the stock a "neutral" rating in a research report on Tuesday, November 5th. JPMorgan Chase & Co. upped their price objective on TG Therapeutics from $30.00 to $43.00 and gave the company an "overweight" rating in a research note on Monday, November 25th. HC Wainwright reiterated a "buy" rating and issued a $55.00 target price on shares of TG Therapeutics in a research report on Wednesday, January 15th. Finally, StockNews.com lowered TG Therapeutics from a "hold" rating to a "sell" rating in a research report on Friday, January 31st. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $40.67.
Check Out Our Latest Stock Report on TGTX
Insider Transactions at TG Therapeutics
In other TG Therapeutics news, CFO Sean A. Power sold 10,021 shares of the business's stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $28.53, for a total transaction of $285,899.13. Following the completion of the transaction, the chief financial officer now directly owns 660,611 shares of the company's stock, valued at $18,847,231.83. The trade was a 1.49 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 10.50% of the company's stock.
About TG Therapeutics
(
Get Free Report)
TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.
Recommended Stories
Before you consider TG Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TG Therapeutics wasn't on the list.
While TG Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
